中药防治肺动脉高压研究现状及创新药物研发  

Research Status of Traditional Chinese Medicine in Pulmonary Hypertension Treatment and Discovery of Innovative Drug

作　　者：牛征 张轩语 付敏 姚丽[1] Niu Zheng;Zhang Xuanyu;Fu Min;Yao Li(School of Pharmacy,Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学药学院,哈尔滨150081

出　　处：《世界科学技术-中医药现代化》2021年第3期856-865,共10页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：国家自然科学基金委员会青年科学基金项目(81302764):蛇床子素对肺动脉高压的网络调控作用与机制研究,负责人:姚丽。

摘　　要：肺动脉高压为恶性肺血管疾病或临床综合征,发病机理涉及复杂的生物学过程和多种分子机制,临床仍缺乏有效治疗药物。尽管单靶点药物的联合应用可有效改善其临床症状,但不能阻止病程进展,且价格昂贵,药物不良反应问题一直未能解决。中药因多成分协同作用、多靶点发挥药效、多途径整合调节疾病的特点,在肺动脉高压的治疗中发挥独特优势,具有良好应用前景和创新药物开发潜力。本文旨在全面系统地梳理近30年中药防治肺动脉高压的研究进展,分析创新药物研发的瓶颈及策略,以期为肺动脉高压的创新药物研发提供有益参考。Pulmonary hypertension(PH) is a malignant pulmonary vascular disease, coupled with complex biological processes and multiple molecular mechanisms. The combined application of target drugs could effectively improve the clinical symptoms, whereas could not inhibit the development of the disease as well as solve the side effects of the drug with high cost. Multiple components of traditional Chinese medicine simultaneously hit multiple targets to treat PH through systemic modulation, which provides a good application prospect for PH treatment. This review comprehensively and systematically summarized the research on traditional Chinese medicine in therapy for PH in the past 30 years and analyzed the bottleneck and strategy of innovative drug development, which provide a basis for the development of innovative drugs in pulmonary hypertension treatment.

关 键 词：肺动脉高压 中药 作用机制 创新药物研发 

分 类 号：R259[医药卫生—中西医结合]